53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma

被引:12
|
作者
Ausborn, Natalie L. [1 ]
Wang, Tong [1 ]
Wentz, Sabrina C. [2 ]
Washington, Mary Kay [2 ]
Merchant, Nipun B. [3 ]
Zhao, Zhiguo [4 ]
Shyr, Yu [4 ]
Chakravarthy, Anuradha Bapsi [1 ]
Xia, Fen [5 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37212 USA
[2] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA
[3] Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37212 USA
[4] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA
[5] Ohio State Univ, Coll Med, Dept Radiat Oncol, Columbus, OH 43210 USA
来源
BMC CANCER | 2013年 / 13卷
基金
美国国家卫生研究院;
关键词
BRCA1; protein; 53BP1; Pancreatic cancer; DNA damage; Repair; HOMOLOGOUS RECOMBINATION; ADJUVANT RADIOTHERAPY; BREAST-CANCER; CA19-9; LEVELS; PANCREATICODUODENECTOMY; EXPERIENCE; RESECTION; SURVIVAL; CHEMOTHERAPY; CARCINOMA;
D O I
10.1186/1471-2407-13-155
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: 53BP1 binds to the tumor suppressor p53 and has a key role in DNA damage response and repair. Low 53BP1 expression has been associated with decreased survival in breast cancer and has been shown to interact with several prognostic factors in non-small cell lung cancer. The role of 53BP1 in pancreatic ductal adenocarcinoma (PDAC) has yet to be determined. We aimed to investigate whether 53BP1 levels interact with established prognostic factors in PDAC. Methods: 106 patients for whom there was tissue available at time of surgical resection for PDAC were included. A tissue microarray was constructed using surgical specimens, stained with antibodies to 53BP1, and scored for expression intensity. Univariate and multivariate statistical analyses were performed to investigate the association between 53BP1 and patient survival with known prognostic factors for survival. Results: The association of 53BP1 with several established prognostic factors was examined, including stage, tumor grade, surgical margin, peripancreatic extension, lymph node ratio (LNR), and CA 19-9. We found that 53BP1 modified the effects of known prognostic variables including LNR and CA 19-9 on survival outcomes. When 53BP1 intensity was low, increased LNR was associated with decreased OS (HR 4.84, 95% CI (2.26, 10.37), p<0.001) and high CA19-9 was associated with decreased OS (HR 1.72, 95% CI (1.18, 2.51), p=0.005). When 53BP1 intensity was high, LNR and CA19-9 were no longer associated with OS (p=0.958 and p=0.606, respectively). Conclusions: In this study, 53BP1, a key player in DNA damage response and repair, was found to modify the prognostic value of two established prognostic factors, LNR and CA 19-9, suggesting 53BP1 may alter tumor behavior and ultimately impact how we interpret the value of other prognostic factors.
引用
下载
收藏
页数:8
相关论文
共 50 条
  • [1] 53BP1 Expression Is a Modifier of the Prognostic Value of Lymph Node Ratio and CA 19-9 in Pancreatic Adenocarcinoma
    Ausborn, N.
    Wang, T.
    Wentz, S. C.
    Washington, M. K.
    Merchant, N. B.
    Zhao, Z.
    Shyr, Y.
    Chakravarthy, A. B.
    Xia, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S309 - S309
  • [2] 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19–9 in pancreatic adenocarcinoma
    Natalie L Ausborn
    Tong Wang
    Sabrina C Wentz
    Mary Kay Washington
    Nipun B Merchant
    Zhiguo Zhao
    Yu Shyr
    Anuradha Bapsi Chakravarthy
    Fen Xia
    BMC Cancer, 13
  • [3] Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma
    Rudnicki, J.
    Agrawal, A. K.
    Grzebieniak, Z.
    Zukrowski, P.
    Zysko, D.
    Jelen, M.
    Kielan, W.
    Sebastian, M.
    Slonina, J.
    Marek, G.
    Duda-Barcik, L.
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2010, 48 (02) : 249 - 261
  • [4] Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
    Joshua G. Barton
    John P. Bois
    Michael G. Sarr
    Christina M. Wood
    Rui Qin
    Kristine M. Thomsen
    Michael L. Kendrick
    Michael B. Farnell
    Journal of Gastrointestinal Surgery, 2009, 13 : 2050 - 2058
  • [5] Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
    Barton, Joshua G.
    Bois, John P.
    Sarr, Michael G.
    Wood, Christina M.
    Qin, Rui
    Thomsen, Kristine M.
    Kendrick, Michael L.
    Farnell, Michael B.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (11) : 2050 - 2058
  • [6] Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma
    Barton, Joshua G.
    Bois, John P.
    Wood, Christina M.
    Qin, Rui
    Kendrick, Michael L.
    Farnell, Michael B.
    GASTROENTEROLOGY, 2008, 134 (04) : A871 - A871
  • [7] Prognostic value of CA 19-9 serum course in pancreatic cancer
    Safi, F
    Schlosser, W
    Falkenreck, S
    Beger, HG
    HEPATO-GASTROENTEROLOGY, 1998, 45 (19) : 253 - 259
  • [8] Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
    Lee, Kyong Joo
    Yi, Seung Woo
    Chung, Moon Jae
    Park, Seung Woo
    Song, Si Young
    Chung, Jae Bock
    Park, Jeong Youp
    YONSEI MEDICAL JOURNAL, 2013, 54 (03) : 643 - 649
  • [9] The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
    Poruk, K. E.
    Gay, D. Z.
    Brown, K.
    Mulvihill, J. D.
    Boucher, K. M.
    Scaife, C. L.
    Firpo, M. A.
    Mulvihill, S. J.
    CURRENT MOLECULAR MEDICINE, 2013, 13 (03) : 340 - 351
  • [10] The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma
    Sato, Yuki
    Fujimoto, Daichi
    Uehara, Keiichiro
    Shimizu, Ryoko
    Ito, Jiro
    Kogo, Mariko
    Teraoka, Shunsuke
    Kato, Ryoji
    Nagata, Kazuma
    Nakagawa, Atsushi
    Otsuka, Kojiro
    Hamakawa, Hiroshi
    Takahashi, Yutaka
    Imai, Yukihiro
    Tomii, Keisuke
    BMC CANCER, 2016, 16